SIA (Acquired by Integra LifeSciences)

Surgical Innovation Associates (SIA) is a medical technology company that develops and commercializes innovative surgical devices for plastic and reconstructive surgery. Its flagship product, DuraSorb®, is a fully absorbable monofilament mesh designed to support soft tissue reconstruction and aesthetic surgery. Launched in 2020, DuraSorb® has seen significant growth, with annual revenue increases of 80-100%. DuraSorb® serves as a synthetic, resorbable surgical matrix that provides temporary support to tissue during healing, addressing a critical need in cosmetic and reconstructive surgery. The product is FDA-approved and is currently undergoing clinical studies to evaluate its safety and effectiveness in implant-based breast reconstruction. SIA primarily serves plastic and reconstructive surgeons, offering advanced materials that enhance patient outcomes in soft tissue repair. In December 2022, SIA entered into an agreement to be acquired by Integra LifeSciences, a global medical technology company. This acquisition aims to accelerate the market penetration of DuraSorb® in the U.S. and expand its availability worldwide, leveraging Integra’s expertise in medical devices for plastic surgery.

• Employees 26
• Founded 2016
• Total Funding $19325000